Genesis expect continued strong achievements with release of interim report

6-Aug-2007

Genesis Research and Development Corporation Ltd announced strong results in their interim financial report this week and expect to make milestone achievements over the coming months.

The company's net cash burn was $2.3 million which was below budget despite expanding the oncology programme. "The oncology programmes have validated a number of targets with significant commercial potential. Development work for delivery to taget tissue types is proceeding well," stated Chief Executive, Stehpen Hall. "Excellent progress has been acheived with all the research programmes during the period. This is expected to lead to milestone achievements over the coming months."

Click to view the company's Financial statements and press release.